Artielle Immunotherapeutics is a clinical stage, venture-backed company headquartered in Portland, OR. Artielle is developing a novel, first-in-class platform of biologic drugs to treat a range of inflammatory and degenerative diseases. The company recently completed Phase I safety studies with its lead compound, RTL1000, in patients with MS and is preparing to initiate Phase I/II trials in the coming months.
Artielle’s platform technology is the subject of a worldwide exclusive license with Oregon Health & Science University that covers the core molecular design of the platform as well as specific therapeutic interventions. The platform is covered by several issued US and foreign patents as well as over 20 patent applications.
